me	edRxiv preprint doi: https://doi.org/10.1101/2022.12.19.22283685; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
1	
2	
3	
4	ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients
5	
6	
7	Yufeng Song ¹ , Regan Myers ¹ , Lila Murphy ^{1,2} , Bailey Brooks ^{1,2} , Jeffrey M. Wilson ³ ,
8	Alexandra Kadl ^{4,5} , Judith Woodfolk ⁴ , Steven L. Zeichner ^{1,6*}
9	
10	
11	
12	¹ Department of Pediatrics, University of Virginia
13	² College of Arts and Sciences, University of Virginia
14	³ Division of Allergy and Clinical Immunology, Department of Medicine, University of
15	Virginia
16	⁴ Department of Medicine, University of Virginia
17	⁵ Department of Pharmacology, University of Virginia
18	⁶ Department of Microbiology, Immunology, and Cancer Biology, University of Virginia
19	
20	*Correspondence: zeichner@virginia.edu
21	

22 Abstract

23 Many mechanisms responsible for COVID-19 pathogenesis are well-established, but 24 COVID-19 includes features with unclear pathogenesis, such as autonomic 25 dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-26 CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme 27 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that 28 have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like 29 catalytic activity - ACE2-like abzymes. To explore this hypothesis, we studied patients 30 hospitalized with COVID-19 who had plasma samples available obtained about 7 days 31 after admission. ACE2 is a metalloprotease that requires Zn²⁺ for activity. However, we 32 found that the plasma from some patients studied could cleave a synthetic ACE2 33 peptide substrate, even though the plasma samples were collected using disodium 34 ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma with 35 synthetic ACE2, no ACE2 substrate cleavage activity was observed unless Zn²⁺ was 36 added or the plasma was diluted to decrease EDTA concentration. After processing 37 samples by 100 kDa size exclusion columns and protein A/G adsorption, which 38 depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2 39 substrate peptide. The data suggest that some patients with COVID-19 develop 40 antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since 41 abzymes can exhibit promiscuous substrate specificities compared to the enzyme 42 whose active site image they resemble, and since proteolytic cascades regulate many 43 physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure 44 COVID-19 pathogenesis.

45

47 Introduction

48	The primary pathology in COVID-19 involves pulmonary disease ¹⁻³ . Other end organ
49	involvement, likely directly attributable to infection with the virus, can include
50	gastrointestinal disease, such as diarrhea, and loss of smell and taste ²⁻⁴ . While the
51	basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling
52	features, including disorders involving high inflammation, disorders of the clotting
53	cascade, and problems with blood pressure homeostasis ^{2, 5, 6} . Some sequelae do not
54	develop until a week or more after infection, suggesting that their pathogenesis may
55	result from secondary processes.
56	
57	Reports suggest that some of the inflammatory processes associated with COVID-19
58	may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small
59	numbers of children who have received COVID-19 vaccines and have had no evidence
60	of infection with SARS-CoV-2, as well as a small number of infants born to mothers with
61	COVID-197 have been described as having multi-system inflammatory syndrome of
62	children (MIS-C) ⁸ .
63	

In addition to acute COVID-19, some patients experience Post-Acute Sequelae of
SARS CoV-2 infection (PASC, sometimes called "long COVID"), a heterogeneous group
of symptoms that continue after acute infection has resolved and can include evidence
of a hyperinflammatory state⁹, persistent coagulopathies, and neurophysiologic
dysregulation, for example aberrant blood pressure regulation. While some clinical
features observable at the beginning of the COVID-19 clinical course, such as SARSCoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

- 71 Virus, may be associated with an increased risk of long COVID¹⁰, the detailed
- 72 pathogenic processes responsible for PASC remain unclear.
- 73

74	Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor
75	for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain
76	(RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a
77	Zn ²⁺ metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory
78	activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin
79	II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to
80	counteract the hypertensive effects of angiotensin II, and so has blood pressure
81	counterregulatory activity compared to ACE. There have been isolated reports and
82	small case series describing persistent hypotension in patients with COVID-19 and
83	patients with PASC without a clearly identified cause ¹¹⁻¹³ .
84	
85	The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation
86	(reviewed in ¹⁴). There is cross-talk between the coagulation, kallikrein-kinin,
87	complement and renin-angiotensin systems ¹⁵ . Some patients with severe COVID-19
88	respiratory disease have been found to have altered regulation of the kallikrein-kinin
89	system in bronchoalveolar lavage fluid ¹⁶ . Abnormalities in the kallikrein-kinin system
90	have been proposed as contributing to the pathogenesis of severe COVID-19 ¹⁷ .
91	
92	Catalytic antibodies, "abzymes" ^{18, 19} , are antibodies that have catalytic activity. When
93	abzymes were first described, they generated considerable excitement. Investigators
94	hypothesized that it would be possible to produce clinically and biotechnologically useful

95 abzymes.

96

90	
97	However, with additional studies, it became clearer that abzyme activity was
98	significantly lower than the activity of more conventional enzymes (kcat/Km values $\sim 10^2$
99	- $10^4 \text{ s}^{-1} \cdot \text{M} \text{ s}^{-1} 2^0 \text{ vs.}$ kcat/Km values of ~ $10^5 \text{ s}^{-1} \cdot \text{M} \text{ s}^{-1}$) ²¹ . Hence, interest in the
100	biotechnological applications of abzymes waned, but an appreciation of the potential
101	role of abzymes in the pathogenesis of disease, including autoimmune disease,
102	continued. High concentrations of abzymes in the circulation may compensate for the
103	abzymes' lower activity to yield clinically significant effects.
104	
105	Patients with autoimmune diseases can make abzymes catalyzing, for example,
106	cleavage of vasoactive intestinal peptide (VIP) ²² , DNA ²³ , immunoglobulin components ²⁴ ,
107	components of the clotting cascade ²⁵⁻²⁷ , and myelin basic protein (MBP) in patients with
108	multiple sclerosis ²⁸ . Abzymes that cleave the HIV envelope protein have been observed
109	to occur in patients with HIV, so there is precedence for the induction of a catalytic
110	antibody by a virus ²⁹ .
111	
112	Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like
113	the activity of a particular enzyme of interest ^{30, 31} . Investigators identify an antibody
114	against an enzyme, and then produce an antibody against the anti-enzyme antibody.

115 For some of the anti-idiotypic antibodies, there is enough resemblance to the active site

of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the

- 117 enzyme^{32, 33}. In some instances, the substrate specificity of the abzyme differs
- 118 substantially from that of the original enzyme^{31, 32, 34}, with the abzyme showing more

119 substrate promiscuity than the original enzyme.

121 The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme 122 on the surface of the target future host cell as its receptor. The RBD is not an antibody, 123 but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic 124 antibody to an antibody against an enzyme, it is plausible to hypothesize that in some 125 cases, an antibody against the RBD might resemble the ACE2 active site and so have 126 catalytic activity. If an antibody directed against the RBD has some resemblance to 127 ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients, 128 might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-129 19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in 130 some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1 131 outlines this hypothesis schematically. We therefore undertook a study to explore 132 whether some COVID-19 patients might have antibodies that can cleave an ACE2 133 substrate. 134

135 We studied plasma samples from a group of 67 patients, with samples obtained 136 relatively early in their disease course, on about the 7th day of hospitalization. As a 137 negative control we purchased pooled human plasma that was collected in late 2018. 138 about a year before the first cases of COVID-19 were described. We tested plasma 139 using an established fluorometric assay for ACE2 activity, which detects cleavage of an 140 ACE2 peptide substrate. We found that some of the patients had ACE2 substrate 141 peptide cleavage activity when the assay was run directly on disodium 142 ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though 143 ACE2 is a metalloprotease that requires Zn²⁺ for activity. Recombinant ACE2 added to 144 plasma did not show ACE2 substrate-cleaving activity unless ZnCl₂ was added to 145 samples at concentrations greater than the EDTA. Processing the samples through a

- 146 100 KDa size exclusion column followed by absorption with protein A/G beads, which
- 147 depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2
- 148 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may
- 149 develop antibodies that have ACE2 substrate cleavage activity.

150

152 Methods

153 Clinical Cohort

154 The clinical cohort was recently described in more detail in another publication³⁵. The 155 hypothesis motivating that work held that COVID-19 would lead to large scale 156 reactivation of lymphotrophic herpesviruses EBV and HHV-6, but the data obtained in 157 the study did not support that hypothesis. In brief, the University of Virginia (UVA) 158 enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted 159 to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients 160 consented were entered into the study. Clinical data were entered into study databases. 161 Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes. 162 Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80 163 C. Study participants (n=67) were adults ages 18 years and above. We used samples 164 obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory 165 drug administration. The predominant viral strain for our sample was the alpha strain with 98.51% of our sample (66 patients) being collected before July of 2021. The sample 166 167 collection protocol was approved by the UVA IRB (HSR #200110), and approval was 168 obtained to work on the specimens (HSR #HSR200362), and it follows the 169 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 170 guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from 171 Valley Biomedical (http://www.valleybiomedical.com/), (Pooled Human Plasma, Cat. No. 172 HP1051PK2, Lot No. 21M2548). This lot of plasma was collected on December 12, 173 2018 and December 13, 2018 (communication with Valley Biomedical technical 174 support), about a year before the start of the COVID-19 pandemic, so it is extremely 175 unlikely that the plasma was derived from any blood from patients infected with SARS-

176 CoV-2. Plasma was aliquoted and stored at -20°C according to manufacturer's

177 instructions.

178

179 Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection

180 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II 181 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297) 182 according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide 183 substrate labeled with a fluor and a quencher. The manufacturer's product information 184 claims a lower limit of detection for an unmodified assay of 400 µU. The manufacturer 185 does not release detailed information concerning the peptide substrate, holding that 186 information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for 187 use as a positive control. 50μ l plasma was added to wells in a 96-well black flat bottom 188 assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark 189 for 15 min. Then, 50μ of substrate pre-diluted according to manufacturer's protocol was 190 added into the wells of the plate, mixing the substrate with the plasma sample. The 191 plate was immediately placed into a SpectraMax® M5 multi-model microplate reader 192 (Molecular Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm) 193 values were measured in kinetic mode every 20 min for a total of 16 hours at 37°C. 194 ACE2 inhibitor provided in the assay kit was also used for additional controls. 195

196 Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples

197 With and Without Added ZnCl₂ or Plasma Dilution

To evaluate whether native ACE2 shed into blood^{36, 37} could contribute to the catalytic
activity observed in the patient plasma samples, we investigated whether EDTA present

- in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.
- 201 EDTA can inhibit the catalytic activity of ACE2, a Zn²⁺ metaloprotease^{38, 39}.
- 202

215	Human Immunoglobulin Depletion and Detection
214	
213	described below.
212	into the wells. Relative Fluorescent Units were measured, and data was analyzed as
211	Then, 50 μ L of substrate (pre-diluted according to manufacturer's protocol) was added
210	and ZnCl ₂ mixture with pre-diluted ACE2 inhibitor served as negative comparisons.
209	concentrations ranging from 0 to 2 mM. Samples containing plasma, recombinant ACE2
208	recombinant ACE2. We also added $ZnCl_2$ to some samples to achieve final
207	conducting the ACE2 assays on the serially diluted samples with the added
206	each well to the samples to the samples according to the manufacturer's protocol,
205	ACE2, provided as a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to
204	from the assay kit and then added and then added 2 μL recombinant positive control
203	We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer

216 To deplete immunoglobulins from the samples, patient plasma samples or pooled 217 healthy donor plasma were centrifuged at 12,000 g at 4 °C for 15 min and supernatants 218 were passed through 0.45 μ m syringe filter (FisherScientific, Cat. #97204) to remove 219 contaminating particulate matter. We then placed 500 μ L of the filtered samples into 220 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. # 221 88503) and centrifuged the columns at 12,000 × g at 4 °C until > 400 μ L of filtrate was 222 produced. To further deplete antibodies in the plasma samples, we then incubated the 223 flow-through fractions with 30 μ L pre-washed Protein A/G Magnetic Beads (Life 224 Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed

225 by magnetic removal of the beads, and repeated the same incubation procedure with 226 another freshly prepared 30 μ L magnetic beads. The resulting processed plasma 227 samples were stored at 4°C for short times (less than 12 hours) or -20 °C for longer 228 times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat. 229 #ab100547) according to the manufacturer's protocol. We added 50 μ L processed 230 samples, as well as standards to multi-microwell strips and incubated them at room 231 temperature for 2.5 hours. Strips were washed with wash buffer and 50 μ L diluted 232 biotin-labeled IgG detection antibody were then added to each well with subsequent 233 HRP-streptavidin incubation after another wash step. Each incubation was performed at 234 room temperature for at least 1 hour. After washing, 100 μ L of TMB One-Step Substrate 235 was added to each well and was incubated for 5 to 15 min at room temperature in the 236 dark with gentle shanking. The reaction was stopped by adding 50 μ L Stop Solution to 237 each well. OD values were read at 450 nm using an accuSkan FC micro-well plate 238 reader (ThermoFisher). IgG concentrations were calculated based on standard curves 239 generated with the same batch of assay strips. Human IgM was measured using a 240 Human IgM ELISA Kit (Invitrogen, Cat. #BMS2098) according to the manufacturer's 241 protocol. Briefly, after washing the strips twice, we added 100 μ L processed samples, 242 as well as standards together with 50 μ L HRP-conjugated antibody to multi-microwell 243 strips and incubated them at room temperature for at least 1 hour. Strips were washed 244 with wash buffer. After washing, 100 μ L of TMB One-Step Substrate was added to each 245 well and was incubated for 5 to 15 min at room temperature in the dark with gentle 246 shanking. The reaction was stopped by adding 100 μ L Stop Solution to each well. OD 247 values were read at 450 nm using an accuSkan FC micro-well plate reader 248 (ThermoFisher). IgM concentrations were calculated based on standard curves 249 generated with the same batch of assay strips.

250

251 **RBD Binding Assays**

- 252 We measured IgG binding to the S-RBD in serum with a quantitative ImmunoCAPTM-
- based system, employing a Phadia 250 (Thermo-Fisher/Phadia), as described⁴⁰. In
- brief, we biotinylated S-RBD (RayBiotech, Peachtree Corners, GA) and conjugated it to
- 255 streptavidin-coated ImmunoCAPTMs (Thermo-Fisher/Phadia). We subtracted
- 256 background signal by subtracting the signal due to unconjugated streptavidin
- 257 ImmunoCAPTM, which was run in parallel with each sample.
- 258

259 Data Analysis

- 260 Since the RFU values for the assays conducted on the samples reached 80% of
- 261 maximum at about 240 min, RFU values observed over 240 min generated by an ACE2
- kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For
- 263 each sample, a value corrected for baseline fluorescence in the sample was obtained
- by the subtracting the baseline RFU value from the value at each subsequent time and
- the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.
- 266 Subsequent statistical analysis and data visualization was done using R (version 4.2.1)
- with the Rstudio environment and packages ggplot2, tidyverse, readr, drc, ggpubr,
- 268 ggh4x, gridExtra, and scales. Samples with the top 20% and a control bottom 10% RFU
- 269 values over 240 min were identified for antibody depletion and further assays.
- 270
- 271

272 **Results**

273 To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled 274 275 with a fluor and a guencher is exposed to sample. ACE2 substrate cleavage activity 276 frees the fluor from guenching, followed by fluorometric evaluation over time. We first 277 established the kit's performance characteristics on commercially purchased EDTA-278 anticoagulated normal human plasma. ACE2 is as Zn²⁺-requiring metalloenzyme. Since EDTA was used as the anticoagulant, to make Zn²⁺ unavailable to the Zn²⁺-requiring 279 280 metalloenzymes of the enzymes involved in the coagulation cascade, we first 281 established whether exogenously added ACE2 could be detected when added to 282 plasma samples under our assay conditions. We found that exogenously added 283 recombinant ACE2 could not be detected, either using commercially obtained pooled 284 plasma or in plasma samples pooled from our patients and obtained from our sample 285 bank, unless Zn²⁺ was added or unless the plasma was diluted (FIG 2). Since no native 286 ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2 287 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due 288 to something other than ACE or another Zn²⁺ metalloprotease.

289

We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical standard lavender top tubes) research participant plasma samples obtained at about the 7th day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe disease. Using these samples, without dilution and without added Zn²⁺, we found that we could detect cleavage of the ACE2 peptide substrate in some of the patients, suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a

scatter plot of the RFU values for the 67 patients studied.

298

299 To determine whether the ACE2 substrate cleavage activity was associated with the 300 presence of immunoglobulin in the samples, we developed an immunoglobulin depletion 301 protocol that includes an initial 0.45 um filtration step to remove large aggregates, 302 followed by a 100 KDa size exclusion column chromatography step, and a subsequent 303 staphylococcal A/G bead absorption step. To test whether patients with high RFU had 304 ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples 305 from patients who had RFU values in the top 20% RFU values and which still had 306 sufficient plasma samples remaining for the immunoglobulin depletion procedure and 307 subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11, 308 13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64) 309 who were among the patients having the bottom 10% of ACE2 substrate cleavage 310 activity and for which sufficient sample was available for the immunoglobulin depletion 311 procedure as negative control. To determine whether our immunoglobulin depletion 312 procedure also depleted IgM in addition to IgG, selected additional samples for which 313 there sufficient plasma remained for the assays, patients 4, 5, 11, 13, 15, 27, 43, 44, 64, 314 and the pooled healthy donor plasma, and determined IgM concentrations before and 315 after immunoglobulin depletion. We also included a purchased pooled EDTA-316 anticoagulated plasma sample as an additional control. For both IgG and IgM, we found 317 that our depletion procedure removed more than 99.99% of the immunoglobulins. 318

Table 2 show the results of the immunoglobulin depletion protocol applied to the patientplasma samples from these patients. The process depleted IgG by a factor of

>>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples. Table 3 shows the
results of assays for IgM run on selected samples for which sufficient sample remained
for the assays. For all samples assayed, the immunoglobulin depletion procedure
removed >99.9% of IgM.

325

326 We then re-assayed these samples to determine whether immunoglobulin depletion

327 was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and

328 found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,

329 depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate

330 cleavage activity.

331

332 If our hypothesis is correct and the ability to cleave an ACE2 substrate is related to Abs 333 against the RBD, then we should be able to observe a correlation between ACE2 334 substrate cleavage activity and the amount of Ab directed against the RBD in the 335 patients' samples. We assaved for anti-RBD Ab binding activity using a modification of 336 an ImmunoCAPTM Assay activity using a Phadia 250 instrument and S-RBD (FIG 6). We 337 found that there was a significant correlation between the amount of Ab in the patient 338 plasma samples capable of binding the RBD and the ACE2 substrate cleavage activity. 339 suggesting that the ACE2 cleavage activity was related to the amount of anti-RBD Ab 340 present in the plasma sample.

341

342

343

345 **Discussion**

346	Our experiments indicate that a fraction of patients with COVID-19 have an activity in			
347	plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity			
348	has divalent cation requirements different from native ACE2 and collocates with			
349	immunoglobulin presence during an immunoglobulin depletion procedure, suggesting			
350	that these patients may have antibodies with abzyme activity.			
351				
352	The ACE2 substrate cleavage activity showed a significant correlation with Ab directed			
353	against the RBD, further supporting the hypothesis that some anti-RBD Abs have ACE2			
354	substrate cleavage activity, but there was considerable spread in the identification of			
355	ACE2 substrate cleavage activity observed for different levels of anti-RBD Ab. However,			
356	this spread would be expected if only a small fraction of Abs elicited against the RBD in			
357	fact had ACE2 substrate cleavage activity, with the initiation and maturation of Ab			
358	responses directed against the RBD resulting, in part, from non-specific processes.			
359				
360	Since abzymes can have a broadened substrate specificity compared to the original			
361	enzyme that they mirror, it is possible that abzymes made in response to SARS-COV-2			
362	infection may cleave a range of substrates, including substrates that form components			
363	of important regulatory cascades, like clotting, blood pressure regulation, and			
364	inflammation processes, which could account for aspects of COVID-19 that cannot be			
365	directly attributed to viral infection and cell and tissue destruction.			
366				
367	Our study had several strengths. We studied a moderate number of patients, with			

368 samples collected prospectively from acutely hospitalized patients with clearly

369 established COVID-19 relatively early in their disease course, but likely approaching at

370 least 2 weeks following initial infection. The patients almost certainly were not admitted 371 immediately following initial infection and the samples were obtained about a week after 372 admission, providing enough time for the development of an initial antibody response to 373 SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide 374 substrate cleavage activity, standard size exclusion columns, protein A/G bead 375 absorption immunoglobulin depletion techniques, and assays for immunoglobulins. The 376 data showing that the ACE2 substrate cleavage activity was present even when there 377 was sufficient EDTA to chelate the Zn²⁺ essential for ACE2 activity suggests that the 378 ACE2 substrate cleavage activity had important characteristics different from native 379 ACE2. The data that the ACE2 substrate cleavage activity was removed from the 380 samples following processing with size exclusion columns and absorption with protein 381 A/G beads suggests that the non- Zn²⁺-requiring ACE2 substrate cleavage activity co-382 localizes with immunoglobulin and the data that ACE2 substrate cleavage activity 383 correlated with Ab against the RBD support the hypothesis that the patients with ACE2 384 substrate cleavage activity may have developed abzymes with this activity. 385 386 However, our study has several limitations. We only studied a limited subset of the patients admitted to our hospital, from patients who consented to the sample banking 387 388 and study and for whom sufficient sample volumes were available. A 389 contemporaneously collected, matched, prospective set of samples from patients 390 without COVID-19 would have been ideal negative controls, but samples from such 391 subjects were not obtained as part of the sample banking effort. We also only 392 conducted the assays on patient samples obtained at a single time, about 7 days after 393 hospitalization, so we have no data from patients who were discharged, transferred, or 394 died prior to day 7 of hospitalization. For this study, we were unable to correlate the

395 presence of ACE-2 abyme activity with clinical disease features. More importantly, in 396 this study we have no data from patients later in their disease course or following 397 convalescence from the acute disease. Inflammatory, coagulopathic, and physiologic 398 dysregulatory phenomena predominate in the later stages of COVID-19 and at least 399 some aspects of PASC and MIS-C appear to result from immune-mediated phenomena. 400 However, some of these patients are treated with anti-inflammatory agents, including 401 intravenous immunoglobulin, which would make the study of these patients for abzyme-402 like activity difficult. If abzymes with promiscuous substrate specificities develop in some 403 COVID-19 patients, some of the clinical features of those disorders could potentially be 404 attributed to abzymes, but this study is not able to directly address such additional 405 hypotheses, which would require additional work. In addition, since abzymes can show 406 substantial substrate specificity spread, it is possible that additional patients in our 407 cohort had abzymes with substrate specificity sufficiently divergent from 408 angiotensinogen that it was not detectable using our assay. It is also possible that 409 COVID-19 patients develop anti-RBD antibodies with abzyme-like activity, but that these 410 antibodies have no clinical significance. Some fraction of normal individuals may have 411 ACE2-like abzyme activity, but this activity could have been diluted in the purchased 412 pooled normal control plasma. However, if the abzyme activity in such patients was 413 similar to that observed in the individual positive patients in this study, that activity would 414 still be $\sim 15\%$ of the activity of the positive patients, given the prevalence of detectable 415 abzyme activity in our cohort, and so would have been likely detectable.

416

417 Finally, our study is merely associational. It is possible that we depleted some other,

418 non-immunoglobulin component of COVID-19 patient plasma that has the ability to

419 cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G

420 treatment procedure. To unequivocally establish that some COVID-19 patients develop 421 anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to 422 isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage 423 activity, and then characterize those monoclonal antibodies in detail. Such work lies 424 outside the perimeters of this current study. It is also possible that some COVID-19 425 patients do, in fact, develop abzymes (ACE2-like – or with other catalytic activity), but 426 that these abzymes have no clinical significance. Additional studies of potential abzyme-427 like activity in COVID-19 patients with different clinical disease manifestations and at 428 different points in their disease course, including long after acute COVID-19, would be 429 needed to establish the overall significance of abyzmes in COVID-19 disease. While 430 understanding the detailed pathogenic significance of abzymes in COVID-19 still 431 requires substantial investigation, the existence of abzymes in COVID-19 is increasingly well-established. In addition to the studies reported here, McConnell and co-workers ⁴¹ 432 433 recently described the existence of abzymes in convalescent plasma COVID-19 434 patients capable of cleaving spike protein with virus neutralization. That two different 435 groups independently found evidence of abzyme activity in plasma from COVID-19 436 patients provides significant support for the hypothesis that COVID-19 patients can 437 develop antibodies with proteolytic activity.

438

Nevertheless, our study offers potential additional insight into some of the difficult-tounderstand clinical features of COVID-19, and if some of the difficult manifestations of COVID-19 are related to the induction of antibodies with abzyme-like activity, that finding may suggest new therapeutic interventions. Some other viruses also have also evolved to use enzymes located on the target host cell surface as their receptors, so it is conceivable that those other viral infections may also elicit clinically problematic anti-

	It is made available under a CC-BY-NC-ND 4.0 International license .
445	viral antibodies. The number of spike protein RBDs presented to the immune system in
446	a natural infection is vastly greater than the number of RBDs presented to the immune
447	system following vaccination, offering many more opportunities for the induction of wide-
448	ranging antibody responses, unlike the antigen exposure resulting from vaccination.
449	While complications following vaccination are very rare and the risk-benefit calculation
450	greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines
451	might also be attributable to the rare induction of anti-RBD antibodies with catalytic
452	activity.
453	
454	Institutional Review Board Statement: The sample collection protocol was approved
455	by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens
456	(HSR #HSR200362).
457	
458	Informed Consent Statement: Informed consent was obtained from all participants
459	involved in the study.
460	Data Availability Statement: Data is presented in the manuscript and the
461	supplements. Raw data can be obtained on request.
462	
463	Acknowledgments and Funding: The study was supported by internal funding from
464	the University of Virginia, including the Manning Fund for COVID-19 Research at UVA
465	the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease
466	Research, a College Council Minera Research Grant, the Coulter Foundation, and
467	NIAID, NIH (R01 AI176515) with sample acquisition costs supported by the HHV-6
468	Foundation. We thank the study participants for graciously agreeing to be research

469 participants, and the research support staff who enrolled the study participants (led by

- 470 Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank the
- 471 University of Virginia Biorepository and Tissue Research Facility for processing the
- 472 samples used in the study and for providing specimens (Technical Director, Patcharin
- 473 Pramoonjago PhD).
- 474
- 475 **Conflicts of Interest:** The authors declare no conflict of interest.
- 476

477 Tables and Figures

- 478
- 479
- 480

Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in ³⁵) (IQR: interquartile range)

Characteristic Age at Admission First Weight (kg)	N = 67, median, (IQR) 60 (48, 66) 91 (76, 112)
Unknown	91 (70, 112) 1
<i>Height (m)</i> Unknown	1.68 (1.60, 1.83) 6
Gender	20 (420/)
Male	20 (42%) 39 (58%)
Race	
African American	23 (34%)
Caucasian	31 (46%)
Other	12 (18%)
Smoking Status	1 (2 10/)
Former	14 (29%)
Never	24 (50%)
Unknown	9 (19%) 19
Need for ICU	19
No	28 (42%)
Yes Need for Intubation	39 (58%)
No	41 (61%)
Yes Blood Turno	26 (39%)
A-	2 (4.8%)
A+	14 (33%)
AB+ B+	1 (2.4%) 3 (7 1%)
O-	1 (2.4%)
O+ Not determined	21 (50%)
Highest Temperature	25
<38	42 (49%)
>38.5	12 (18%) 12 (18%)
>40	1 (1.5%)
Length of Stay (Days)	10 (5, 22)
6	1
10-20	2
>30	3 2 (
Highest D-Dimer	605 (280, 2,074)
Highest CRP BMI	10 (4, 16) 33 (27, 38)
Need for Vasopressors	44 (669()
Dexamethasone	44 (00 %)
Yes Prednisone	41 (61%)
Yes Methylprednisolone	3 (13%)
Yes	5 (22%)
Yes	4 (6%)
Remdesivir Yes	27 (40%)
Creatinine	1.00 (0.80, 1.45)
Hgb IENa3	12.4 (10.8, 13.6) 45 (36, 72)
Not determined	45
Highest Ferritin	1277 (7, 7161)
Highest Troponin	0
<0.04	47 (73%)
0.04-0.4 >0.6	12 (18%) 3 (5%)
Not determined	5
Highest Creatinine	1.10 (0.90, 1.80)

Table 2. Plasma IgG concentration before and after antibody depletion for selected 556

patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2 557 substrate cleavage activity with results shown in FIG 4. 558

559

	Patient	IgG Concentration		IgG depletion
60	(#) -	Pre ª mg/ml	Post⁵ ng/ml	(%)
	4	14.62	0.67	>99.99%
	5	12.50	1.48	>99.99%
	9	24.40	0.96	>99.99%
	11	75.41	0.17	>99.99%
	13	26.35	2.46	>99.99%
	15	13.27	2.47	>99.99%
	27	10.53	2.40	>99.99%
	43	29.07	0.87	>99.99%
	44	11.17	2.29	>99.99%
	47	13.15	1.85	>99.99%
	48	12.32	2.06	>99.99%

a: IgG concentration in plasma before antibody depletion

561 562 b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

564 Table 3. Plasma IgM concentration before and after antibody depletion for selected 565 patients.

566

Patient	lgM Cor (m	IgM Concentration (mg/ml)	
(#)	Pre ^a	Post ^b	(%)
4	0.875	1.43E-05	>99.99%
5	0.753	1.44E-05	>99.99%
11	0.7916	7.99E-06	>99.99%
13	0.644	1.41E-05	>99.99%
15	2.250	1.08E-05	>99.99%
27	0.549	1.40E-05	>99.99%
43	1.560	1.34E-05	>99.99%
44	3.243	1.41E-05	>99.99%
64	0.915	8.22E-06	>99.99%
Pooled Healthy Donor	0.4852	1.3568E-05	>99.99%

a: IgM concentration in plasma before antibody depletion

b: IgM concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

569

571 Figure Legends

572	
573	FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
574	COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
575	potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
576	against the RBD may then have a conformation sufficiently like ACE2 to have
577	proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
578	suggests that the catalytic activity of some antibodies will have a substrate specificity
579	like ACE2, but because the negative image of RBD present antibodies is imperfect,
580	some antibodies with proteolytic activity will have an altered substrate specificity,
581	potentially affecting multiple proteolytic regulatory cascades.
582 583	FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
584	undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
585	ACE2 is a Zn ²⁺ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
586	detectable when exogenous ACE2 was added to the plasma, unless Zn^{2+} was also
587	added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
588	Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
589	indicating that the activity was specific for ACE2. The findings indicate that no native
590	ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
591	ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
592	be due to something other than ACE or another Zn ²⁺ metalloprotease.
593	
594	FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
595	COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the

596 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus

control samples. Several patients, including the 11 patients we selected for further study
(4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU
values and had sufficient plasma sample remaining for the immunoglobulin depletion
protocol, showed an ability to cleave ACE2 substrate. (HDP: commercially purchased
pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;
HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative
samples).

604

605 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples

from the 67 patients evaluated in this study. The top 20% of values are plotted in red,

the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top

608 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays

609 before and after immunoglobulin depletion shown in FIG 5.

610

611 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin 612 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 613 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which 614 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after 615 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by 616 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays 617 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative 618 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among 619 the bottom 10% of RFU values and had sufficient plasma remaining for the 620 immunoglobulin depletion protocol. The data suggest that for the 11 patients

- 621 demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate
- 622 cleavage activity was depleted in an immunoglobulin-associated manner.
- 623
- 624 FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
- 625 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
- 626 plasma samples were determined using ImmunoCAP[™] antibody binding assay. The
- 627 negative control pooled human plasma is indicated by the red symbol. The patient
- 628 plasma samples are indicated in green. The negative control plasma values were
- 629 omitted in the calculation of the r- and p-values.
- 630

631 FIG 1. FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The 632 SARS-COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the 633 surface of a potential host cells. The RBD has a partial negative image of ACE2. Some 634 antibodies against the RBD may then have a conformation sufficiently like ACE2 to 635 have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further 636 suggests that the catalytic activity of some antibodies will have a substrate specificity 637 like ACE2, but because the negative image of RBD present antibodies is imperfect, 638 some antibodies with proteolytic activity will have an altered substrate specificity, 639 potentially affecting multiple proteolytic regulatory cascades.

- 640
- 641
- 642



FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in 645 646 undiluted EDTA-anticoagulated pooled plasma samples with and without added ZnCl₂. ACE2 is a Zn²⁺ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was 647 648 detectable when exogenous ACE2 was added to the plasma, unless Zn²⁺ was also 649 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2. 650 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions. 651 indicating that the activity was specific for ACE2. The findings indicate that no native ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any 652 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should 653 654 be due to something other than ACE or another Zn²⁺ metalloprotease. 655



658 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with 659 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus 660 control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 661 662 47, 48) that showed an ability to cleave ACE2 substrate. (HDP: commercially purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant 663 664 human ACE2; HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma 665 from negative samples).



FIG 4. Scatter plot of the background corrected RFU values for the plasma samples from the 67 patients evaluated in this study. The top 20% of values are plotted in red, the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays before and after immunoglobulin depletion shown in FIG 5.

- 673 674
- 675



678 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin 679 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 680 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which 681 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after 682 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by 683 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays 684 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative 685 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among 686 the bottom 10% of RFU values and had sufficient plasma remaining for the 687 immunoglobulin depletion protocol. The data suggest that for the 11 patients 688 demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2 689 substrate cleavage activity was depleted in an immunoglobulin-associated manner. 690



Time (min)

FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
plasma samples were determined using ImmunoCAP[™] antibody binding assay. The
negative control pooled human plasma is indicated by the red symbol. The patient
plasma samples are indicated in green. The negative control plasma values were
omitted in the calculation of the r- and p-values.





708 **References**

709 1. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, 710 Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ, 711 Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States, 712 January 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-70. PMC7017962 713 714 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, 2. 715 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, 716 Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients 717 infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 718 15;395(10223):497-506. PMC7159299 719 720 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the 3. 721 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 722 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 723 2020 Apr 7;323(13):1239-42. 724 725 Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK, 4. 726 Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng 727 PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in 728 Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic 729 Review. Open Forum Infect Dis. 2020 Jun;7(6):ofaa199. PMC7284010 730 731 Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang 5. 732 Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the 733 classification and prognosis evaluation of COVID-19: a retrospective cohort study. 734 Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397 735 736 Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, 6. 737 Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van 738 Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, 739 Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo 740 C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature 741 predicts COVID-19 severity and survival. Nat Med. 2020 Oct:26(10):1636-43. 742 PMC7869028 743 De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, 744 7. 745 Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to 746 Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger 747 Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 748 2022;14(4):750. 749 750 8. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, 751 McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, 752 Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported 753 cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA 754 who received a COVID-19 vaccine, December, 2020, through August, 2021: a 755 surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

756 757 Crook H. Raza S. Nowell J. Young M. Edison P. Long covid-mechanisms, risk 9. 758 factors, and management. Bmj. 2021 Jul 26;374:n1648. 759 760 Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,, Zhang 10. R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C., 761 762 Lee, I.,, Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J., 763 Yang, F., Duncombe,, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S., 764 DeGottardi, Q., May, D.H., Taniguchi R, Gittelman, R.M. Klinger, M., Snyder, T.M. 765 Roper, R., Wojciechowska, G., Murray, K., Edmark R, Evans, S., Jones, L., Zhou, Y., 766 Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington, W.R. W, J.A., Cochran, R.A., 767 Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos, 768 C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N., 769 Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A., 770 Chu, H., Hood., L. G. R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R., 771 Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022. 772 773 Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response 11. 774 Syndrome, and COVID-19: A Clinical Conundrum. Anesth Analg. 2020 775 Sep;131(3):e175-e6. PMC7302068 776 777 12. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim 778 PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management 779 strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e7. PMC7850225 780 Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric 781 13. 782 Hypertensive Patients? Medicina (Kaunas). 2021 Jun 18;57(6). PMC8235779 783 784 14. Hillmeister P, Persson PB. The Kallikrein–Kinin system. Acta Physiologica. 785 2012;206(4):215-9. 786 787 15. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the 788 renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev 789 Immunol. 2022 Jul;22(7):411-28. PMC8579187 790 791 Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, 16. 792 Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S, 793 Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbriele C, Meersseman 794 P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M, 795 Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in 796 bronchoalveolar lavage fluid of patients with severe COVID-19. eBioMedicine. 2022 797 2022/09/01/;83:104195. 798 799 17. Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-800 angiotensin systems in COVID-19 infection. Peptides. 2021 2021/01/01/:135:170428. 801 802 18. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec 803 19;234(4783):1566-70. 804

805 19. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody.
806 Science. 1986 Dec 19;234(4783):1570-3.

810
811 21. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The
812 moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme
813 parameters. Biochemistry. 2011 May 31;50(21):4402-10.

814

Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic
hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun
9;244(4909):1158-62.

819 23. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov
820 AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.
821

Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural
catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL
fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.

826 25. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S.
827 Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May
828 30;39(21):6459-65.
829

Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon
A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis
mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun
1;180(11):7714-20.

27. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N,
Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of
antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999
Sep;5(9):1044-7.

839

Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN,
Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM,
Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D,
Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific
degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6.
PMC1324791

Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB,
Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov
AG. Induction of a protein-targeted catalytic response in autoimmune prone mice:
antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan
10;45(1):324-30.

<sup>807
808 20.</sup> Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem.
809 2000;69:751-93.

853 30. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic 854 antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5. 855 856 Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using 31. 857 an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl 858 Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9. 859 860 32. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic 861 antibodies as functional internal images of enzyme active sites: production of a catalytic 862 antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct 863 1;90(19):8876-80. PMC47463 864 865 Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as 33. 866 functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar 867 31;750:265-70. 868 869 Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle 34. 870 B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic 871 antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec 872 18;46(50):14598-609. 873 874 35. Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu 875 H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in 876 Acute COVID-19 Patients. Viruses. 2022;14(9):1872. 877 878 García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G, 36. 879 Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic 880 Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-881 19. Biomolecules. 2022 Jan 5;12(1). PMC8774087 882 883 37. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, 884 Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS 885 One. 2021;16(9):e0257016. PMC8415618 886 887 Tanna A, Guarino L, Tam FWK, Rodriguez-Cubillo B, Levy JB, Cairns TD, Griffith 38. 888 M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of antineutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the 889 890 international histological classification and other prognostic factors. Nephrology Dialysis 891 Transplantation. 2014;30(7):1185-92. 892 893 39. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in 894 biological fluid (ACE2). Hypertension: Springer; 2017. p. 101-15. 895 Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan 40. 896 G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A, 897 Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute 898 Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. Int Arch Allergy 899 Immunol. 2021;182(5):417-24. PMC8018212 900

901 41. McConnell SA, Sachithanandham J, Mudrak NJ, Zhu X, Farhang PA, Cordero

902 RJB, Wear MP, Shapiro JR, Park HS, Klein SL, Tobian AAR, Bloch EM, Sullivan DJ,

903 Pekosz A, Casadevall A. Spike-protein proteolytic antibodies in COVID-19 convalescent

904 plasma contribute to SARS-CoV-2 neutralization. Cell Chem Biol. 2023 Jul

905 20;30(7):726-38.e4. PMC10288624